Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy
ViiV announced the start of a phase III clinical trial for the safety and efficacy of dolutegravir&rilpivirine for adult patients with HIV.
-
Results announcement for the first quarter 2015
GSK reports Q1 sales of £5.6 billion; Core EPS of 17.3p (-16%) CER
-
GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID
Today announced the submission of a marketing application to the EMA for a gene therapy (GSK2696273) to treat patients with a rare disease
-
FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US
GSK and THRX announced approved once-daily treatment of asthma in patients aged 18+ BreoEllipta is not for the relief of acute bronchospasm.
-
GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2 which does not diminish in the age groups studied
Shingles is a significant public health burden, more than 90% of adults aged 50 years and over are at risk.
-
Malaria vaccine candidate has demonstrated efficacy over 3-4 years of follow-up
Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate published today in The Lancet.
-
GSK to establish global vaccines R&D centre in the US
New hub based in Rockville, MD expands GSK’s global vaccines R&D footprint
-
GSK statement on meningitis vaccination in the UK
GSK reached an agreement with the UK’s Department of Health that will enable babies to receive its meningitis B vaccine through the NHS
-
GSK receives approval for Encruse® Ellipta® in Japan for the treatment of COPD
Two further GSK products, Duac® Combination Gel and Synflorix™, also gain approval in Japan.
-
GSK’s 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US
GSK is encouraging scientists to submit their novel early drug discovery research proposals into its Discovery Fast Track Challenge
-
GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma
GSK and THRX announced the outcome of the joint meeting for a once-daily inhaled treatment for asthma in patients aged 12 years and older.
-
GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
GSK today announced the start of a phase III programme to evaluate the efficacy of retosiban, an investigational oxytocin antagonist.
-
GSK becomes partner in new global fund to accelerate dementia research
Company makes $25m (approx £17m) investment in first-of-its-kind venture capital fund focused on dementia
-
GSK transaction
Exclusively intended for persons who are not residents of the United States and who are not physically present in the United States.
-
GSK transaction launch
Exclusively intended for persons who are not residents of the United States and who are not physically present in the United States
-
GSK announces major new commitment to Asia
GlaxoSmithKline (GSK) is strengthening its presence in Singapore by establishing a new global headquarters for Asia
-
GSK completes major three-part transaction with Novartis
GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion
-
GlaxoSmithKline plc announces changes to its Board
GSK today announces that Sir Christopher Gent will step down as Chairman of GSK at the Company’s Annual General Meeting on 7 May 2015
-
Update on three-part transaction with Novartis
GSK today announces good progress on obtaining clearances and approvals to enable completion of its three-part transaction with Novartis
-
GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG
GSK today announced that it has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland.